Natera Inc
NASDAQ:NTRA

Watchlist Manager
Natera Inc Logo
Natera Inc
NASDAQ:NTRA
Watchlist
Price: 161.21 USD -0.41%
Market Cap: 21.3B USD
Have any thoughts about
Natera Inc?
Write Note

Natera Inc
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Natera Inc
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Natera Inc
NASDAQ:NTRA
Cash from Investing Activities
$173.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Investing Activities
-$19.7B
CAGR 3-Years
-121%
CAGR 5-Years
N/A
CAGR 10-Years
-20%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Investing Activities
-$4B
CAGR 3-Years
31%
CAGR 5-Years
6%
CAGR 10-Years
-13%
Amgen Inc
NASDAQ:AMGN
Cash from Investing Activities
-$27.7B
CAGR 3-Years
-304%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Investing Activities
-$3.8B
CAGR 3-Years
N/A
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Investing Activities
-$2.9B
CAGR 3-Years
8%
CAGR 5-Years
-7%
CAGR 10-Years
-17%
No Stocks Found

Natera Inc
Glance View

Market Cap
20B USD
Industry
Biotechnology
Economic Moat
Narrow

In the dynamic world of biotechnology, Natera Inc. stands out as a leader in genetic testing and diagnostics. Founded with the vision of transforming how we understand our genetic blueprint, Natera has grown into a significant player, leveraging advanced molecular biology to decode human DNA with remarkable precision. The company's flagship technology, a proprietary cell-free DNA platform, underpins an array of genetic tests that cater to diverse needs in the fields of oncology, women's health, and organ health. Through this technology, Natera offers prenatal screening tests like Panorama, which can detect chromosomal abnormalities early in pregnancy, providing crucial insights for expectant parents. Additionally, the company's oncology solutions, such as Signatera, assist in tailoring personalized cancer treatment regimens by detecting minimal residual disease, thereby offering oncologists a powerful tool for disease management. Financially, Natera sustains its operations through a robust business model that combines direct billing and reimbursements from insurance providers, alongside partnerships with healthcare institutions. By offering innovative testing solutions, Natera generates revenue through test processing fees and related services. The company's growth is fueled by its investments in research and development, constantly pushing the boundaries to enhance test accuracy and expand into new markets. This strategic focus has not only broadened its portfolio but also fortified its ties with healthcare professionals and institutions worldwide. In navigating the complex landscape of genetic science, Natera continues to play a pivotal role in advancing personalized medicine, positioning itself as a linchpin in the future of healthcare diagnostics.

NTRA Intrinsic Value
55.82 USD
Overvaluation 65%
Intrinsic Value
Price

See Also

What is Natera Inc's Cash from Investing Activities?
Cash from Investing Activities
173.4m USD

Based on the financial report for Sep 30, 2024, Natera Inc's Cash from Investing Activities amounts to 173.4m USD.

What is Natera Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 1Y
5%

Over the last year, the Cash from Investing Activities growth was 5%.

Back to Top